**Our current and future activities**

**Alphanosos** discovers, patents and produces antimicrobial and anti-cancer preparations.

These blends are selected and optimized with our own **Artificial Intelligence** algorithms and rapid discovery platform.

✓ They are already used in veterinary hygiene products and human cosmetics and evaluated as additives for aquaculture and animal feed in general.

✓ Later, we will use them in dietary supplements and finally as drugs. The initial target diseases will be bacterial infections, in particular those responsible for certain chronic inflammations and those resistant to conventional antibiotics, and cancers.

✓ These short terms products will lead us to our ultimate vision of providing health preservation products personalized on the basis of somatic and microbiota genetic profiles and Artificial Intelligence.

**Our first commercial products**

**Animals dermatology products**

Lotion (launched) and shampoos (launch 3Q2019) for dogs and cats with skin problems, in particular for dog pyoderma (a type of infectious eczema)

These products are sold through commercial distributors, starting with pharmacies, toileting and pet shops, and later veterinaries.

Some experts estimate that 20% of dogs suffer from such skin problems and are without satisfactory solution ( 173 million dogs in top 10 dog countries, potential market is 800 million Euro at 25€ public price).

**Human dermatology products**

Human dermatology products: launch 2Q2020. In EU, as a dermo-cosmetic (BIO/COSMOS) adapted to skins with problems such as eczema, atopic dermatitis, acne, psoriasis and alopecia.

Commercial launch will be through internet and distributors, with a target of product licensing.

This product will later be developed as a botanical drug in the USA.

A cosmetic ingredient is already sold to a European cosmetic company. All these dermatological markets together sum up into the 5-10 billion Euro range with high unmet needs.

**COVID-19 Coronavirus Outbreak**

Alphanosos is initiating contacts with academic, institutional and charities partners to discuss a project for the rapid discovery of a COVID-19 treatment (also an opportunity to start on seasonal flu, Ebola, Lhassa, etc...).

**Intellectual Property**

The patent position of our discoveries is very strong as witnessed from the European Patent Office report of our first antimicrobial patent (WO2018083115). This patent has just undergone international extension into 71 countries.
Our current product development pipeline

### Pre-clinical R&D projects

**Natural antibiotics for animal feed additives**

Especially for farming animals such as fish and shrimps in aquaculture, and poultry/broilers and pigs in farms.

The global feed antibiotic additive market is in the 3-4 billion Euro range. Discussions for partnerships and tests are ongoing with major players in the agribusiness field.

**Natural preservatives Functional foods and drinks**

Developed with our artificial intelligence and edible plants, they will offer unique properties without the need for “chemical compounds”.
- Replacing biocides in foods and cosmetics
- Wellbeing and health products
- Taste and performance products
These markets sum-up into a 3-4 billion Euro range.

### At medium term and/or through strategic partnerships opportunities

Alphanosos is studying many other applications to our proprietary technology like natural antibiotics for animals and humans (gonorrhea, tuberculosis, antimicrobial resistance), preventive and curative oncology, biodefense and, based on somatic and microbiota genetic profiles, personalized prevention of microorganism induced chronic inflammatory diseases such as Lyme’s, Alzheimer’s, atherosclerosis, inception of certain cancers, etc.

It is also envisioned to work with partners on viruses such as seasonal flu, and also pain, inflammation, aging, etc.

### Financial aspects

Alphanosos intends to be monthly cash-positive in the course of 2021 and generate products sales and partnerships revenues in the 400~600k€ range in 2020 and over a million Euro turnover in 2021. Current cash-burn is close to 45k€ per month with 5 employees with break-even targeted in 2022. Long term revenues are expected to be through a mix of sales and royalties on licenses to our patents.

The current investment opportunity targets 1.6-2.4MM€ for approximately 8-12% of shares post-money.

It will allow Alphanosos, commensurate to sales progression and by increasing headcount and outsourcing certain marketing, regulatory and technical aspects, to:

- Initiate urgent research for rapid AI-guided discovery of a natural and edible treatment against 2019-nCoV
- Speeding-up revenue generation through strengthening commercialization efforts and resources,
- Setting-up a GMP facility for food/feed additives and cosmetic ingredients,
- Developing additional finished products (veterinary, dermo-cosmetics, aquaculture),
- Speeding-up microbiology and oncology R&D (including animal models) and IP protection,
- Performing cosmetic clinical studies and preparing for medical clinical trials as botanical drugs,
- Strengthening strategic business development.

Exit opportunities are envisaged as early as 2022/23.

### Contact

**Pascal Mayer, PhD, CEO & co-founder**

+33 659 856 881 / +33 982 216 506

pascal.mayer@alphanosos.com

Alphanosos S.A.S.
20-22 rue Henri et Gilberte Goudier
63200 Riom, France

www.alphanosos.com

---

Alphanosos document, intended solely to the recipient of associated message and his/her related parties, March 2020